ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BXP Beximco Pharma

39.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Beximco Pharma LSE:BXP London Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 39.00 37.00 41.00 39.00 38.00 39.00 5,319 08:00:06

Beximco Pharmaceuticals Ltd Commencement of Second Product Export to the US (6582V)

07/11/2017 7:00am

UK Regulatory


Beximco Pharma (LSE:BXP)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Beximco Pharma Charts.

TIDMBXP

RNS Number : 6582V

Beximco Pharmaceuticals Ltd

07 November 2017

7 November 2017

BEXIMCO PHARMACEUTICALS LTD.

Beximco Pharma commenced its second product export to the US

Remains Bangladesh's only pharmaceutical company to export pharmaceutical products to the US

Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Sotalol Hydrochloride (80 mg, 120 mg and 160 mg), a generic version of the cardiovascular drug Betapace, to the US. Following the successful launch of Carvedilol to the US in August 2016, this is the second product from Beximco Pharma to be exported to the US.

According to QuintlesIMS data, the market size for Satalol Hydrochloride (including all strengths) in the US is $23 million. The first consignment was delivered on 29 October 2017 and the product will be distributed through the Company's existing partner in the US.

Managing Director of Beximco Pharma, Mr. Nazmul Hassan MP commented:

"We are delighted to strengthen our presence in the US with the launch of our second product in this market. With the export of our first product to the US in August 2016, we began a new era for the pharmaceutical industry in Bangladesh that we continue to build with the launch of Sotalol. Beximco Pharma remains the only Bangladeshi company to export pharmaceutical products to the US, which is a validation of our expertise in offering specialised generic products in a global setting. With our growing pipeline for the US, we will focus on increasing our presence in the world's largest pharma market in the coming years."

In June 2015, Beximco Pharma became the first Bangladeshi pharmaceutical company audited and approved by the US Food and Drug Administration (FDA).

Beximco Pharma is one of the largest exporters of pharmaceuticals in Bangladesh, winning the country's National Export Trophy (Gold) a record five times, the highest national accolade for export. The Company currently has a global footprint in more than 50 countries and has been accredited by a number of global regulatory authorities, including US FDA, AGES, Austria (EU), TGA Australia, Health Canada, GCC and TFDA.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, ext.20080

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

Northland Capital Partners Limited (Broker)

Gerry Beaney / Tom Price

Tel: +44 (0)20 3861 6625

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 3727 1000

Notes to Editors:

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,500 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFQLFBDFFFFBQ

(END) Dow Jones Newswires

November 07, 2017 02:00 ET (07:00 GMT)

1 Year Beximco Pharma Chart

1 Year Beximco Pharma Chart

1 Month Beximco Pharma Chart

1 Month Beximco Pharma Chart

Your Recent History

Delayed Upgrade Clock